RE:RE:Drum beat until May 25thIt has been suggested that mBC may be going forward without a CPI.
As the science guys have not responded to this, I have decided to look at the situation from my lay perspective.
In no particular order:
1. mBC. Phase 3 Bridging Study in Chinese patients, Not Recruiting. An oral ASCO Poster that is most promising. The possibility of AA. with Pela plus Paclitaxel.
2. Multiple Myeloma. Pela plus Opdivo. Not recruiting. The very interesting AMBUSH trial with Keytruda. This latter trial a Phase 2, and Recruiting.
3. GOBLET with Tecentiq. Remarkable results from the PDAC cohort, and CRC results in the near future, and more from PDAC.
4. TNBC IRENE with Retifanlimab. Recruiting.
5. Promising Preclinical CAR T. ASCO Poster HGG. Note the use of the word Re-activatable.
I have likely missed something and/or made mistakes in the above. Still I think ONC/Y is in a very good place. The bases seem to be covered. Cheers